Long-Term Results Confirm Subcutaneous Trastuzumab ’s Efficacy in HER2+ Breast Cancer
The long-term results of the phase III HannaH trial confirmed the similarity between the subcutaneous and intravenous formulation of trastuzumab in patients with HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 6, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

HER2 Testing Inaccessible for Many Women With Breast Cancer HER2 Testing Inaccessible for Many Women With Breast Cancer
A survey of HER2 testing of breast cancer in 45 countries highlights major issues around access and affordability in low- and middle-income countries (LMIC), with some problems extending even to upper-middle-income countries (UMIC).Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 4, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

FDA Approves Genentech's Kadcyla for Adjuvant Treatment of People With HER2-Positive Early Breast Cancer
South San Francisco, CA -- May 3, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Kadcyla (ado-trastuzumab emtansine) for adjuvant (after... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 4, 2019 Category: Drugs & Pharmacology Source Type: news

De-Escalating Treatment in Metastatic HER2+ Breast Cancer: Is it Safe?
Researchers tested omitting chemotherapy from a treatment regimen involving dual blockade with pertuzumab and trastuzumab in patients with metastatic HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 1, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

HER2 positive breast cancer: Treatment de-escalation needs to be personalized
(European Society for Medical Oncology) De-escalation approaches in the treatment of women with HER2 positive breast cancer need to be personalized, according to Dr. Carmen Criscitiello, European Institute of Oncology, Milan, Italy. Her comments come on the occasion of the presentation of updated research results at the inaugural ESMO Breast Cancer Congress 2019, May 2-4, 2019, in Berlin, Germany. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 1, 2019 Category: Cancer & Oncology Source Type: news

Global HER2 testing survey raises questions about priorities for breast cancer resources
(European Society for Medical Oncology) A global survey of HER2 testing has raised questions about how resources should be spent on potentially lifesaving HER2 targeted therapies for breast cancer, especially in poorer countries. The results were presented at the ESMO Breast Cancer Congress 2019, Berlin, May 2-4, 2019. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 29, 2019 Category: Cancer & Oncology Source Type: news

Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Roche today announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer. (Source: Roche Media News)
Source: Roche Media News - April 23, 2019 Category: Pharmaceuticals Source Type: news

Roche launches new VENTANA HER2 Dual ISH companion diagnostic test for breast and gastric cancer patients eligible for targeted therapy
Roche today announced the launch of the new VENTANA HER2 Dual ISH DNA Probe Cocktail assay for the detection of the HER2 biomarker in breast and gastric cancer. (Source: Roche Investor Update)
Source: Roche Investor Update - April 23, 2019 Category: Pharmaceuticals Source Type: news

Seven-Year Follow-Up Results Can Help HER2+ Breast Cancer Patients Avoid Overtreatment
The combination of trastuzumab and paclitaxel'represents an important step forward in de-escalating therapy'for HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 12, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

MyPathway Subanalysis Backs Combination HER2-Targeting Antibodies in Colorectal Cancer
Investigators studied a combination of  pertuzumab and trastuzumab in patients with metastatic, HER2-positive colorectal cancer. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news

For Advanced Sarcoma, Adding Lymphodepletion to HER2-Targeted CAR T-Cell Therapy Excites
A phase I trial evaluated the safety and efficacy of adding  lymphodepletion to HER2-targeted T-cell therapy in patients with advanced HER2-positive sarcoma. (Source: CancerNetwork)
Source: CancerNetwork - April 9, 2019 Category: Cancer & Oncology Authors: Christina Bennett, MS Source Type: news

Ibrance Approval Expanded to Include Men With Breast Cancer
THURSDAY, April 4, 2019 -- U.S. Food and Drug Administration approval of Ibrance (palbociclib) capsules has been widened to include men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 4, 2019 Category: General Medicine Source Type: news

FDA expands approved use of metastatic breast cancer treatment to include male patients
The FDA is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 4, 2019 Category: American Health Source Type: news

FDA expands approved use of metastatic breast cancer treatment to include male patients
The U.S. Food and Drug Administration today is extending the indication of Ibrance (palbociclib) capsules in combination with specific endocrine therapies for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in male patients. (Source: World Pharma News)
Source: World Pharma News - April 4, 2019 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

FDA Approves Ibrance (palbociclib) for the Treatment of Men with HR+, HER2- Metastatic Breast Cancer
April 4, 2019 -- Pfizer (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application (sNDA) to expand the indications for Ibrance (palbociclib) in combination with an aromatase inhibitor or... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 4, 2019 Category: Drugs & Pharmacology Source Type: news

Strategy for Treatment of Stage IV HER2+ Gastric Cancer Strategy for Treatment of Stage IV HER2+ Gastric Cancer
This case presents a patient successfully treated with a novel strategy for stage IV HER2-positive gastric cancer, which usually has a poor prognosis.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 3, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Surgery Tied to Improved Survival in Stage IV Breast Cancer Surgery Tied to Improved Survival in Stage IV Breast Cancer
A retrospective analysis showed that for women with HER2+ stage IV breast cancer, surgery was associated with higher survival rates compared with women who did not undergo surgery.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 3, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

On the TRAIL of a Solution to Trastuzumab Resistance in HER2+ Breast Cancer
A genomic and proteomic analysis of HER2+ breast cancer cell lines that are resistant to trastuzumab found a deregulation of the cell death pathway known as TRAIL. (Source: CancerNetwork)
Source: CancerNetwork - April 3, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

AACR: Surgery Tied to Improved Survival in HER2 + Breast Cancer
In addition to targeted medication, adjuvant therapy, surgery improves survival in stage IV disease (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 3, 2019 Category: Cancer & Oncology Tags: Gynecology, Oncology, Surgery, Conference News, Source Type: news

Mastectomy Seems to Boost Advanced HER2+ Survival
Surgery was associated with a 44% increased chance of survival, assuming that most patients were also treated with chemo or targeted drug therapies, the study found. (Source: WebMD Health)
Source: WebMD Health - April 3, 2019 Category: Consumer Health News Source Type: news

AACR: Surgery Tied to Improved Survival in HER2 & #43; Breast Cancer
TUESDAY, April 2, 2019 -- For patients with human epidermal growth factor receptor 2-positive (HER2+) stage IV breast cancer, surgery is associated with improved survival, according to a study presented at the annual meeting of the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2019 Category: Pharmaceuticals Source Type: news

Surgery Tied To 44% Increased Survival In Women With Advanced Breast Cancer
(CNN) — Surgery is tied to improved chances of survival among stage 4 breast cancer patients, a new study suggests, but who has access to surgery and who doesn’t can vary drastically, based on factors including income level and where treatment is administered. Surgery to remove tumors was associated with a 44% increased chance of survival within an average followup period of 21 months, according to the abstract, to be presented at the American Association for Cancer Research’s annual meeting in Atlanta this week. “If breast surgery is to be considered by patients and providers when deciding treatmen...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - April 2, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News Breast Cancer CNN Source Type: news

Are Assessment Guidelines for HER2 Status Leading to Many False Positives?
Researchers tested whether the use of recommended alternative control probes to classify HER2 status in breast cancer could lead to substantial false positives. (Source: CancerNetwork)
Source: CancerNetwork - April 2, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Surgery associated with increased survival for patients with HER2+ stage 4 breast cancer
(American Association for Cancer Research) Surgery was associated with higher survival rates for patients with HER2-positive (HER2+) stage 4 breast cancer compared with those who did not undergo surgery, according to results presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2019 Category: Cancer & Oncology Source Type: news

Breast cancer study by UCR medical student could help patients live longer
(University of California - Riverside) A student at the University of California, Riverside, presented research results at the annual meeting of the American Association for Cancer Research, or AACR, in Atlanta showing that surgery is associated with higher survival rates for patients with HER2-positive stage 4 breast cancer compared with those who did not undergo surgery. The protein HER2, or human epidermal growth factor receptor 2, can play a role in the development of breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 2, 2019 Category: Cancer & Oncology Source Type: news

AACR 2019: Tarloxotinib promising against NRG1-fusion cancers
(University of Colorado Anschutz Medical Campus) University of Colorado Cancer Center study presented at AACR 2019 shows that the clinical-stage drug, tarloxotinib, is active against NRG1-fusion cancers, in addition to the HER2/EGFR cancers for which the drug was originally designed. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 1, 2019 Category: Cancer & Oncology Source Type: news

HER2-targeted CAR T-cell therapy shows promising antitumor activity in patients with sarcoma
(American Association for Cancer Research) A combination of chemotherapy and chimeric antigen receptor (CAR) T cells designed to target the protein HER2 was found to be safe and showed clinical responses in pediatric and adult patients with advanced HER2-positive sarcoma, according to results from a phase I clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: news

' Encouraging Activity' for Dual Anti-HER2 Tx in HER2+, KRAS Wild-Type MCRC (CME/CE)
(MedPage Today) -- MyPathway data support use in heavily pretreated HER2-amplified metastatic colorectal cancer (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 17, 2019 Category: Gastroenterology Source Type: news

Hope for breast cancer patients who suffer heart woes from chemo
Fifteen percent of people with aggressive HER2-positive tumors (around 9,000 US women a year) suffer side effects from their chemo. A Stanford study found a way to predict and mitigate that. (Source: the Mail online | Health)
Source: the Mail online | Health - March 14, 2019 Category: Consumer Health News Source Type: news

Dual Anti-HER2 Tx Shows Benefit in Advanced CRC
(MedPage Today) -- Strategy yielded a 40% response rate in KRAS wild-type, HER2-amplified disease (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - March 12, 2019 Category: Gastroenterology Source Type: news

TILs in Patients on Trastuzumab/Pertuzumab-Based Chemo TILs in Patients on Trastuzumab/Pertuzumab-Based Chemo
Evaluation of baseline TIL percentage may provide prognostic information to patients receiving dual HER2 blockade for breast cancer.Journal of the National Cancer Institute (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 11, 2019 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer T-DM1 Benefits'Striking' in HER2+ Early Breast Cancer
Lidia Schapira provides her perspective on a recent study of trastuzumab emtansine in residual invasive HER2+ breast cancer.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 7, 2019 Category: Consumer Health News Tags: Hematology-Oncology Viewpoint Source Type: news

FDA Approves Subcutaneous Trastuzumab Formulation for HER2+ Breast Cancer
The US Food and Drug Administration has approved the subcutaneous administration of trastuzumab for patients with HER2-overexpressing breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 5, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Adding Checkpoint Inhibition in Trastuzumab-Resistant HER2+ Breast Cancer
An early-phase trial tested the combination of pembrolizumab with trastuzumab in patients with PD-L1 –positive, trastuzumab-resistant, advanced HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - March 4, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Media News)
Source: Roche Media News - February 28, 2019 Category: Pharmaceuticals Source Type: news

FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta ™ (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment of certain people with HER2-positive early breast cancer (node-positive, or node-negative and ER/PR-negative or with one high-risk feature) in combination with chemotherapy and HER2-positive metast atic breast cancer in combination with paclitaxel or alone in people who have received one or more chemotherapy regimens for metastatic disease. (Source: Roche Investor Update)
Source: Roche Investor Update - February 28, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Herceptin Hylecta for Subcutaneous Injection in Certain HER2-Positive Breast Cancers
South San Francisco, CA -- February 28, 2019 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin Hylecta (trastuzumab and hyaluronidase-oysk) for... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2019 Category: Drugs & Pharmacology Source Type: news

PET scans show biomarkers could spare some breast cancer patients from chemotherapy
(Johns Hopkins Medicine) In an effort to further individualize therapy and avoid over-treating patients, researchers at the Johns Hopkins Kimmel Cancer Center report a new study using PET scans has identified a biomarker that may accurately predict which patients with one type of HER2-positive breast cancer might best benefit from standalone HER2-targeted agents, without the need for standard chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 21, 2019 Category: Cancer & Oncology Source Type: news

NICE draft guidance recommends pertuzumab for early treatment of breast cancer
NICE has published guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes. (Source: NHS Networks)
Source: NHS Networks - February 19, 2019 Category: UK Health Source Type: news

' Remarkable' New Benefit in HER2+ Breast Cancer'Remarkable' New Benefit in HER2+ Breast Cancer
Roughly half of patients with HER2-positive, early stage breast cancer have residual disease after initial drug therapy and then surgery; T-DM1 may improve their outcomes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 13, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Can Trastuzumab Therapy Continue After LVEF Decline in HER2+ Breast Cancer?
The researchers looked at cardiac outcomes among a group of HER2+ breast cancer patients treated with trastuzumab who had an asymptomatic LVEF decline of
Source: CancerNetwork - February 11, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

Breast cancer cells shifted into HER2 positive status with bold new strategy
(Scripps Research Institute) One of the most effective breast cancer drugs, Herceptin, is only available to people whose tumors test HER2-positive. That's only one in five breast cancer patients. That could change with a new approach from Scripps Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2019 Category: Cancer & Oncology Source Type: news

Is DFS an Appropriate Surrogate for OS in Early HER2+ Breast Cancer?
The study findings suggest that disease-free survival can continue to be used as a surrogate endpoint in the setting of early HER2+ breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - February 7, 2019 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news

UCLA ’s Dennis Slamon awarded Sjöberg Prize for pioneering cancer research
Dr. Dennis Slamon, director of the Revlon/UCLA Women ’s Cancer Research Program, has been named a co-winner of the 2019 Sjöberg Prize by the Royal Swedish Academy of Sciences and Sweden’s Sjöberg Foundation. Honored for his groundbreaking research that led to the development of successful targeted cancer therapies, Slamon shares the award with D r. Brian Druker of Oregon Health& Science University.The Sj öberg Prize has been awarded annually since 2016 to recognize outstanding cancer research. The honor carries a prize of $1 million — $100,000 as award money and $900,000 to fund future ...
Source: UCLA Newsroom: Health Sciences - February 5, 2019 Category: Universities & Medical Training Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Media News)
Source: Roche Media News - February 5, 2019 Category: Pharmaceuticals Source Type: news

Roche submits supplemental biologics license application to the US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
Roche today announced completing the submission of a supplemental Biologics License Application to the US Food and Drug Administration (FDA) for Kadcyla ® (trastuzumab emtansine) for adjuvant (after surgery) treatment of people with HER2-positive early breast cancer (eBC) with residual disease after neoadjuvant (before surgery) treatment. (Source: Roche Investor Update)
Source: Roche Investor Update - February 5, 2019 Category: Pharmaceuticals Source Type: news

Identification of HER2 IHC-Negative, FISH+ Breast Cancers Identification of HER2 IHC-Negative, FISH+ Breast Cancers
Both immunohistochemistry for protein expression or fluorescent in situ hybridization for gene amplification can be used to determine HER2 status in breast cancer--but what if they don't agree?American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - February 4, 2019 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Use of Image Analysis to ID HER2 Status in Breast Cancer Outlined
FRIDAY, Feb. 1, 2019 -- Recommendations have been developed to improve accuracy, precision, and reproducibility in the interpretation of human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) results for breast cancer with use of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 1, 2019 Category: Pharmaceuticals Source Type: news

NICE recommends pertuzumab for early HER2-positive breast cancer
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2019 Category: Drugs & Pharmacology Source Type: news

Guide for HER2 Testing That's Not'by Eye'Guide for HER2 Testing That's Not'by Eye '
Quantitative image analysis is an alternative to breast cancer diagnostic tests that require a visual review by a pathologist.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 28, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news